We are live on ! Find out more
ADIL icon

Adial Pharmaceuticals
ADIL

14 hedge funds and large institutions have $495K invested in Adial Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

826,249% more capital inflows, than outflows

Capital inflows: $454K | Capital outflows: $55

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

56% more funds holding

Funds holding: 9 → 14 (+5)

17% more ownership

Funds ownership: 4.85% → 21.84% (+17%)

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$349K
2
Renaissance Technologies
Renaissance Technologies
New York
+$50.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$32.4K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$9.26K
5
UBS Group
UBS Group
Switzerland
+$6.74K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$55

ADIL Hedge Fund Activity: Q4 2023 in Review

14 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2023, worth a combined $495K — up 202% from $164K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ADIL positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $349K. The largest seller was Morgan Stanley, exiting entirely with an estimated $55 sold.

  • 14 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2023, up from 9 in Q3 2023.
  • Funds reported $495K of Adial Pharmaceuticals stock for Q4 2023, up 202% quarter-over-quarter.
  • 6 funds opened new Adial Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +5 holders.
  • The largest Adial Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $349K added.
  • The largest Adial Pharmaceuticals seller in Q4 2023 was Morgan Stanley, an estimated $55 sold.

Based on aggregated 13F filings for Q4 2023.